Indivior initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes initiated coverage of Indivior (INDV) with a Buy rating and $27 price target The firm sees a favorable risk/reward at current share levels, saying the durability of Sublocade revenue in the growing long-acting injectable market for opioid use disorder is underappreciated. In addition, Indivior’s operational focus could drive meaningful cost reduction efforts in non-core areas of the company, the analyst tells investors in a research note.